Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial

Clinical Infectious Diseases

Volumn 60, Issue 11, 2015, Pages 1642-1649

  Torre Cisneros, Julian ^a   San Juan, Rafael ^b   Rosso Fernández, Clara M ^c   Silva, J Tiago ^b   Muñoz Sanz, Agustin ^d   Muñoz, Patricia ^e   Miguez, Enrique ^f   Martín Dávila, Pilar ^g   López Ruz, Miguel Angel ^h   Vidal, Elisa ^a   Cordero, Elisa ^c   Montejo, Miguel ⁱ   Blanes, Marino ^j   Fariñas, M Carmen ^k   Herrero, Jose Ignacio ^l   Rodrigo, Juan ^m   Aguado, Jose Maria ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL INFANTA CRISTINA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^l UNIVERSITY CLINIC OF NAVARRA   (Spain)

^m HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

more..

Author keywords

investigator driven clinical trial; levofloxacin; tenosynovitis; tuberculosis

Indexed keywords

ISONIAZID; LEVOFLOXACIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; INVESTIGATIVE PROCEDURES; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSOCOMIAL PNEUMONIA; OPEN STUDY; PANCYTOPENIA; PEPTOCLOSTRIDIUM DIFFICILE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TENOSYNOVITIS; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; URINARY TRACT INFECTION; VOMITING; ADVERSE EFFECTS; ANTIBIOTIC PROPHYLAXIS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAFT RECIPIENT; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; LEVOFLOXACIN; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TENOSYNOVITIS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84930385074     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ156     Document Type: Article

References (32)

1. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solidorgan transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276-84.
2. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
3. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solidorgan transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. B Infect Dis 2009; 48:1657-65.
4. Benito N, Sued O, Moreno A, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. B 2002; 74:1381-6.
5. Lui SL, Li FK, Choy BY, Chan TM, Lo WK, Lai KN. Long-term outcome of isoniazid prophylaxis against tuberculosis in Chinese renal transplant recipients. Transpl Infect Dis 2004; 6:55-6.
6. Sud K, Muthukumar T, Singh B, et al. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients. Methods Find Exp Clin Pharmacol 2000; 22:647-9.
7. Horsburgh CR Jr, Feldman S, Ridzon R, Infectious Diseases Society of A. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000; 31:633-9.
8. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-7.
9. Centers for Disease C, Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51: 998-9.
10. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123:102-6.
11. Centers for Disease Control and Prevention. American Thoracic Society. B: adverse event data and revised American Thoracic Society/ CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. B Morb Mortal Wkly Rep 2003; 52:735-9.
12. AEMPS. Nota Informativa: Moxifloxacino (Actira, Proflox, Octegra): Riesgo de alteraciones hepáticas y reacciones cutáneas graves. España: Ministerio de Sanidad y Consumo de España, 2008.
13. NCI Guidelines for Investigators. Adverse event reporting requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs. Vol. USA: National Cancer Institute, 2013. Available at: http://ctep.cancer.gov/protocol Development/electronic-applications/docs/aeguidelines.pdf, http://ctep. B.gov/protocolDevelopment/electronic-applications/docs/aeguide lines.pdf. Accessed 1 December 2014.
14. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. B 2010; 11:32.
15. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67:2077-99.
16. Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014; 18:912-8.
17. Holland DP, Sanders GD, Hamilton CD, Stout JE. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One 2012; 7:e30194.
18. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. B is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). B statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161(4 Pt 2): S221-47.
19. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. B J Antimicrob Agents 2002; 20:464-7.
20. Sato K, Tomioka H, Sano C, et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 2003; 52:199-203.
21. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:852-7.
22. Gonzalez-Martin J, Garcia-Garcia JM, Anibarro L, et al. [Consensus document on the diagnosis, treatment and prevention of tuberculosis]. B Infect Microbiol Clin 2010; 28:297 e1-20.
23. Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC, Luh KT. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 2009; 48:1526-33.
24. Ortega M, Soriano A, Garcia S, et al. [Tolerability and safety of levofloxacinin long-term treatment]. Rev Esp Quimioter 2000; 13:263-6.
25. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-52.
26. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47(suppl 3):32-7; discussion 44-8.
27. Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005; 128:1406-13.
28. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33:194-200.
29. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013; 12:497-505.
30. Sendzik J, Shakibaei M, Schafer-Korting M, Lode H, Stahlmann R. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents 2010; 35:366-74.
31. de La Red G, Mejia JC, Cervera R, Llado A, Mensa J, Font J. B Achilles tendinitis with spontaneous rupture induced by levofloxacin in a patient with systemic sclerosis. Clin Rheumatol 2003; 22:367-8.
32. Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. B 2014; 312:2106-14.